Activins and Their Related Proteins in Colon Carcinogenesis: Insights from Early and Advanced Azoxymethane Rat Models of Colon Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2016 Nov 13

PMID 27835986

Citations 5

Authors

Bassem Refaat

Adel Galal El-Shemi

Amr Mohamed Mohamed

Osama Adnan Kensara

Jawwad Ahmad

Shakir Idris

Affiliations

Soon will be listed here.

Abstract

Background: Activin-A may exert pro- or anti-tumorigenic activities depending on cellular context. However, little is known about its role, or the other mature activin proteins, in colorectal carcinoma (CRC). This study measured the expression of activin βA- & βB-subunits, activin type IIA & IIB receptors, smads 2/3/4/6/7 and follistatin in CRC induced by azoxymethane (AOM) in rats. The results were compared with controls and disseminated according to the characteristics of histopathological lesions.

Methods: Eighty male Wistar rats were allocated into 20 controls and the remaining were equally divided between short 'S-AOM' (15 weeks) and long 'L-AOM' (35 weeks) groups following injecting AOM for 2 weeks. Subsequent to gross and histopathological examinations and digital image analysis, the expression of all molecules was measured by immunohistochemistry and quantitative RT-PCR. Activin-A, activin-B, activin-AB and follistatin were measured by ELISA in serum and colon tissue homogenates.

Results: Colonic pre-neoplastic and cancerous lesions were identified in both AOM groups and their numbers and sizes were significantly (P < 0.05) greater in the L-AOM group. All the molecules were expressed in normal colonic epithelial cells. There was a significantly (P < 0.05) greater expression of βA-subunit, IIB receptor and follistatin in both pre-neoplastic and cancerous tissues. Oppositely, a significant (P < 0.05) decrease in the remaining molecules was detected in both AOM groups. Metastatic lesions were only observed within the L-AOM group and were associated with the most significant alterations of all molecules. Significantly higher concentrations of activin-A and follistatin and lower activin-AB were also detected in both groups of AOM. Tissue and serum concentrations of activin-A and follistatin correlated positively, while tissue activin-AB inversely, and significantly with the numbers and sizes of colonic lesions.

Conclusions: Normal rat colon epithelial cells are capable of synthesising, controlling as well as responding to activins in a paracrine/autocrine manner. Colonic activin systems are pathologically altered during tumorigenesis and appear to be time and lesion-dependent. Activins could also be potential sensitive markers and/or molecular targets for the diagnosis and/or treatment of CRC. Further studies are required to illustrate the clinical value of activins and their related proteins in colon cancer.

Citing Articles

Inhibin subunit beta B (INHBB): an emerging role in tumor progression.

Liu Y, Zhou Q, Zou G, Zhang W J Physiol Biochem. 2024; 80(4):775-793.

PMID: 39183219 DOI: 10.1007/s13105-024-01041-y.

Enhanced anti-cancer effects of oestrogen and progesterone co-therapy against colorectal cancer in males.

Mahbub A, Aslam A, Elzubier M, El-Boshy M, Abdelghany A, Ahmad J Front Endocrinol (Lausanne). 2022; 13:941834.

PMID: 36263327 PMC: 9574067. DOI: 10.3389/fendo.2022.941834.

In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network.

Adnan Almaimani R, Aslam A, Ahmad J, El-Readi M, El-Boshy M, Abdelghany A Cancers (Basel). 2022; 14(6).

PMID: 35326689 PMC: 8946120. DOI: 10.3390/cancers14061538.

Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status.

Refaat B, Zekri J, Aslam A, Ahmad J, Baghdadi M, Meliti A Pathol Oncol Res. 2021; 27:1610032.

PMID: 34867090 PMC: 8634429. DOI: 10.3389/pore.2021.1610032.

TGFβ and activin A in the tumor microenvironment in colorectal cancer.

Zessner-Spitzenberg J, Thomas A, Krett N, Jung B Gene Rep. 2020; 17.

PMID: 32154442 PMC: 7061929. DOI: 10.1016/j.genrep.2019.100501.

References

Antsiferova M, Werner S . The bright and the dark sides of activin in wound healing and cancer. J Cell Sci. 2012; 125(Pt 17):3929-37. DOI: 10.1242/jcs.094789. View

Brown C, Woodruff T, Matzuk M . Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat Genet. 2000; 25(4):453-7. DOI: 10.1038/78161. View

Thompson T, Lerch T, Cook R, Woodruff T, Jardetzky T . The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell. 2005; 9(4):535-43. DOI: 10.1016/j.devcel.2005.09.008. View

Refaat B, El-Shemi A, Ashshi A, Mahamid E, Al-Qadi N . Pegylated Interferon-α Modulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar Rat. Mediators Inflamm. 2015; 2015:414207. PMC: 4506924. DOI: 10.1155/2015/414207. View

Yoshimi N, Morioka T, Kinjo T, Inamine M, Kaneshiro T, Shimizu T . Histological and immunohistochemical observations of mucin-depleted foci (MDF) stained with Alcian blue, in rat colon carcinogenesis induced with 1,2-dimethylhydrazine dihydrochloride. Cancer Sci. 2004; 95(10):792-7. PMC: 11159780. DOI: 10.1111/j.1349-7006.2004.tb02183.x. View

Zhou X, Wang J, Lu J, Song Y, Kwak K, Jiao Q . Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010; 142(4):531-43. DOI: 10.1016/j.cell.2010.07.011. View

Jain P, Mondal S, Sinha S, Mukhopadhyay M, Chakraborty I . Diagnostic and prognostic significance of different mucin expression, preoperative CEA, and CA-125 in colorectal carcinoma: A clinicopathological study. J Nat Sci Biol Med. 2014; 5(2):404-8. PMC: 4121924. DOI: 10.4103/0976-9668.136207. View

Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A . Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015; 6(2):185-200. PMC: 4311092. DOI: 10.3978/j.issn.2078-6891.2014.112. View

Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K . Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer. J Exp Clin Cancer Res. 2003; 22(2):315-20. View

10.

Le Bras G, Loomans H, Taylor C, Revetta F, Andl C . Activin A balance regulates epithelial invasiveness and tumorigenesis. Lab Invest. 2014; 94(10):1134-46. PMC: 4309391. DOI: 10.1038/labinvest.2014.97. View

11.

Zhang Y, Bao Y, Yang M, Wu Y, Yu C, Huang Y . Activin A induces SLC5A8 expression through the Smad3 signaling pathway in human colon cancer RKO cells. Int J Biochem Cell Biol. 2010; 42(12):1964-72. DOI: 10.1016/j.biocel.2010.08.007. View

12.

Freeman T, Smith J, Chen X, Washington M, Roland J, Means A . Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology. 2011; 142(3):562-571.e2. PMC: 3343368. DOI: 10.1053/j.gastro.2011.11.026. View

13.

Pholnukulkit P, Sonoyama K, Kawabata J . Activin A induces phosphorylation of Smad2 but not complex formation of Smad2 with Smad4 in human colon cancer cell line HT-29. Biosci Biotechnol Biochem. 2003; 67(9):2042-4. DOI: 10.1271/bbb.67.2042. View

14.

Tan C, Hirokawa Y, Gardiner B, Smith D, Burgess A . Colon cryptogenesis: asymmetric budding. PLoS One. 2013; 8(10):e78519. PMC: 3804607. DOI: 10.1371/journal.pone.0078519. View

15.

Pretlow T, ORiordan M, Somich G, Amini S, Pretlow T . Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis. 1992; 13(9):1509-12. DOI: 10.1093/carcin/13.9.1509. View

16.

Refaat B, Ashshi A, El-Shemi A, Azhar E . Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy. Mediators Inflamm. 2015; 2015:287640. PMC: 4417604. DOI: 10.1155/2015/287640. View

17.

Fleming N, Jorissen R, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M . SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2012; 73(2):725-35. DOI: 10.1158/0008-5472.CAN-12-2706. View

18.

Jung B, Gomez J, Chau E, Cabral J, Lee J, Anselm A . Activin signaling in microsatellite stable colon cancers is disrupted by a combination of genetic and epigenetic mechanisms. PLoS One. 2009; 4(12):e8308. PMC: 2789408. DOI: 10.1371/journal.pone.0008308. View

19.

Pai S, Fuloria J . Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol. 2016; 8(1):99-104. PMC: 4714150. DOI: 10.4251/wjgo.v8.i1.99. View

20.

Al-Hajeili M, Marshall J, Smaglo B . Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer. Oncology (Williston Park). 2016; 30(1):10-6. View